Myeloproliferative neoplasms (MPN) often carry the gain-of-function mutation V617F of the Janus kinase 2 (JAK2), which leads to a constitutive activation of the downstream signaling cascade. This evidence concerns the gene JAK2 and myeloproliferative disorder.